[1] |
Sung H, Ferlay J, Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.DOI: 10.3322/caac.21660.
|
[2] |
|
[3] |
|
[4] |
Denisenko TV, Budkevich IN, Zhivotovsky B.Cell death-based treatment of lung adenocarcinoma[J]. Cell Death Dis, 2018, 9(2):117.DOI: 10.1038/s41419-017-0063-y.
|
[5] |
Minguet J, Smith KH, Bramlage P.Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives [J]. Int J Cancer. 2016, 138(11):2549-2561. DOI: 10.1002/ijc.29915.
|
[6] |
Love MI, Huber W, Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J]. Genome Biology, 2014, 15(12):550. DOI: 10.1186/s13059-014-0550-8.
|
[7] |
Yu G, Wang LG, Han Y,et al.clusterProfiler: an R package for comparing biological themes among gene clusters[J]. Omics, 2012, 16(5):284-287.DOI: 10.1089/omi.2011.0118.
|
[8] |
Subramanian A, Tamayo P, Mootha VK,et al.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci USA, 2005, 102(43):15545-15550.DOI: 10.1073/pnas.0506580102.
|
[9] |
Evers L, Messow CM.Sparse kernel methods for high-dimensional survial data[J]. Bioinformatics, 2008, 24(14):1632-1638.DOI: 10.1093/bioinformatics/btn253.
|
[10] |
Guo W, Huai Q, Zhang G,et al.Elevated heterogeneous nuclear ribonucleoprotein C expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma[J]. Front Oncol, 2021(10):598437.DOI: 10.3389/fonc.2020.598437.
|
[11] |
Park YM, Hwang SJ, Masuda K, et al. Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4[J]. Mol Cell Biol, 2012, 32(20):4237-4244.DOI: 10.1128/MCB.00443-12.
|
[12] |
Wang LC, Chen SH, Shen XL,et al.M6A RNA methylation regulator HNRNPC contributes to tumorigenesis and predicts prognosis in glioblastoma multiforme[J]. Front Oncol, 2020(10):536875. DOI: 10.3389/fonc.2020.536875.
|
[13] |
Zhang Y, Chen W, Pan T,et al.LBX2-AS1 is activated by ZEB1 and promotes the development of esophageal squamous cell carcinoma by interacting with HNRNPC to enhance the stability of ZEB1 and ZEB2 mRNAs[J]. Biochem Biophys Res Commun, 2019, 511(3):566-572.DOI: 10.1016/j.bbrc.2019.02.079.
|
[14] |
Huang H, Han Y, Zhang C,et al.HNRNPC as a candidate biomarker for chemoresistance in gastric cancer[J]. Tumour Biol, 2016, 37(3):3527-3534.DOI: 10.1007/s13277-015-4144-1.
|
[15] |
Hu J, Cai D, Zhao Z,et al.Suppression of heterogeneous nuclear ribonucleoprotein C inhibit hepatocellular carcinoma proliferation,migration,and invasion via Ras/MAPK signaling pathway[J]. Front Oncol, 2021(11):659676.DOI: 10.3389/fonc.2021.659676.
|
[16] |
Su Z, Liu X, Xu Y,et al.Novel reciprocal fusion genes involving HNRNPC and RARG in acute promyelocytic leukemia lacking RARA rearrangement[J]. Haematologica, 2020, 105(7):e376-e378.DOI: 10.3324/haematol.2019.244715.
|
[17] |
Ying P, Li Y, Yang N.et al.Identification of genetic variants in m6A modification genes associated with pancreatic cancer risk in the Chinese population[J]. Arch Toxico, 2021, 95(3):1117-1128.DOI: 10.1007/s00204-021-02978-5.
|
[18] |
Hodge RG, Ridley AJ.Regulating Rho GTPases and their regulators[J]. Nat Rev Mol Cell Biol, 2016, 17(8):496-510.DOI: 10.1038/nrm.2016.67.
|
[19] |
Jiang M, Jia K, Wang L,et al.Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy[J]. Acta Pharm Sin B, 2021, 11(10):2983-2994.DOI: 10.1016/j.apsb.2021.01.003.
|
[20] |
Duffy MJ, Synnott NC, Crown J.Mutant p53 as a target for cancer treatment[J]. Eur J Cancer, 2017(83):258-265.DOI: 10.1016/j.ejca.2017.06.023.
|
[21] |
Shen Y, Liu S, Fan J,et al.Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNPC-p53 protein interactions[J]. EMBO Rep, 2017, 18(4):536-548.DOI: 10.15252/embr.201643139.
|